VivoSeq
Oncology

Undifferentiated Pleomorphic Sarcoma

9

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Undifferentiated Pleomorphic Sarcoma is an early-stage landscape with 9 programs across 9 companies. The most active players are Iovance Biotherapeutics, Inc., Bristol-Myers Squibb, Tracon Pharmaceuticals Inc..

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

50/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2T

Tracon Pharmaceuticals Inc.

1 program

Phase 2S

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

1 program

Phase 2C

Coherus Oncology, Inc.

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Monoclonal antibody

6 of 10 classified programs — the dominant modality here.

40%ALL OTHERSSmall molecule330%Cell therapy110%

Monoclonal antibody leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

6

clinical trials

Active, not recruiting2 · 33%
Unknown status2 · 33%
Terminated1 · 17%
Completed1 · 17%

Clinical Trials

Trial Activity

6 trials

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Active, not recruiting·TTracon Pharmaceuticals Inc.·Phase 2·NCT04480502·207 enrolled
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03307616·32 enrolled
Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Completed·RRoyal Marsden NHS Foundation Trust·Phase 1/2·NCT03123276·25 enrolled
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT05017103·6 enrolled
A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
Unknown status·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT05193214·30 enrolled
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
Unknown status·—·Phase 2·NCT03946943·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)